Our study indicated comparable results with the PEONY study, both in the dual HER2 blockade group and single blockade control group, suggesting that pyrotinib plus trastuzumab and docetaxel might be an alternative option for HER2-positive breast cancer in the neoadjuvant setting. The gene discussed is ERBB2; the disease is breast carcinoma.